Extensions

For US Patent 8291236, here is a detailed breakdown of its prosecution and term information:

Patent Term Adjustments (PTA) and Patent Term Extensions (PTE):

• Patent Term Adjustment (PTA): PTA adds time to a patent's term to compensate for certain delays caused by the USPTO during prosecution. These delays typically involve the USPTO failing to issue an office action within 14 months, responding to an applicant's reply within four months, or issuing the patent within four months of the issue fee payment, or if the application is pending for more than three years. The USPTO automatically calculates PTA and includes the determination in the Issue Notification Letter. While the exact PTA granted for US8291236 is not explicitly stated in the provided text, the patent's expiration date of 2030-06-04 indicates that some adjustment may have been applied to extend it beyond the typical 20 years from its filing date (2004-12-07).
• Patent Term Extension (PTE): PTE is available under the Hatch-Waxman Act for patents claiming products (e.g., human and veterinary pharmaceuticals, medical devices) that require regulatory approval prior to commercial marketing. This extension aims to restore a portion of the patent term lost during the regulatory review period. PTE can be a maximum of five years, and the total patent life with PTE cannot exceed 14 years from the date of FDA approval. Only one patent can be extended per regulatory review period. There is no indication in the provided text that US8291236 has received a Patent Term Extension under 35 U.S.C. § 156, as this type of extension is typically associated with pharmaceutical or medical device products requiring FDA approval, which is not the subject matter of this patent.

Continuation Applications, Divisional Applications, and Related Family Members:
The provided patent information indicates that US8291236 has the following related applications and publications:

• Application number: US11/007,116 (This is the application number that led to the issuance of US8291236).
• Other versions/publications: US20060123246A1 (This is a publication of the application).
• Priority to:
  • CN200580041806.4A (Chinese application)
  • JP2007545471A (Japanese application)
  • EP05824991A (European application)
  • PCT/US2005/039794 (PCT International application)
  • US13/612,663 (This appears to be a later-filed US application, which could be a continuation or divisional, leading to US8667304B2).

Based on the information, the patent US8291236 is part of a larger patent family that includes international filings and at least one subsequent US application (US13/612,663, which issued as US8667304B2). Without direct access to the USPTO's PAIR system or official family data, it is not definitively stated whether US13/612,663 is a continuation or divisional of US11/007,116, but its priority claim suggests a relationship.

Projected Expiration Date:
US Patent 8291236 is currently active and is projected to expire on 2030-06-04.